TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03769298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
Study: NCT03862859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
Study: NCT03025009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3192767
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3192767
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin Peglispro
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC.
Study: NCT02474654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 100 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: 100 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: 100 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: 100 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 600 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 600 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 600 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine with Epinephrine
Description: 0.5% 1:400,000 30ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine with Epinephrine
Description: 0.5% 1:400,000 30ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine with Epinephrine
Description: 0.5% 1:400,000 30ml
Study: NCT03993639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Single dose of SC administration
Study: NCT00040794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT00142116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
Study: NCT00979212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
Study: NCT02786927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA device
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA device
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA device
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA device
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules for use in HANDIHALER device
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
Study: NCT02615613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Acceptability Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High acceptability meal
Study: NCT02800785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
Description: Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
Study: NCT01790191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated consumption of basic artichoke purée.
Description: In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated consumption of sweet artichoke purée.
Description: In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated exposure to fat artichoke purée.
Description: In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
Study: NCT00778401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin tablets 800 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin tablets 800 mg
Study: NCT03403179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Remediation
Description: Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
Study: NCT01189721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol, sevoflurane
Description: Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol, sevoflurane
Description: Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.
Study: NCT03566680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Description: Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
Study: NCT00660374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Soft-treat-to-target dose titration scheme, injection s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX1000
Description: Soft-treat-to-target dose titration scheme, injection s.c.
Study: NCT02446509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation - Delayed
Description: The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
Study: NCT03025009

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT02577497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Study: NCT04490161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous reinstallation of cerebrospinal fluid
Description: 10ml of CSF will be taken under sterile conditions from the external ventricular drain and immediately administered intravenously.
Study: NCT03672643

Intervention type: DRUG
Group type: OTHER
Intervention: Crizotinib
Description: receive crizotinib orally
Study: NCT04430192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Patients 1-10 will be given 5GBq of 177Lu-PSMA. Patients 11-20 will be given 2 cycles of 5GBq of 177Lu-PSMA, separated by 6 weeks.
Study: NCT02786927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules for use in HANDIHALER device
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules for use in HANDIHALER device
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules for use in HANDIHALER device
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
Study: NCT04571008

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention will last at least 16 weeks in the form of two capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).
Study: NCT05029700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise training
Description: Combined exercise group (CEG) performed 30 minutes of aerobic training and also received trunk stabilization training in about 30 minutes after a 10-minute resting period. CEG received treatment 2 times a week for 8 weeks. During trunk stabilization training, the participants were taught how to contract the transversus abdominis and multifidus muscles. Due to the progression protocol, endurance levels of trunk muscles were increased by holding each posture for longer periods. The training was started with theraband resistance, which could be repeated between 10-12 repetitions, and the repetition time was increased up to 20. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
Study: NCT02786927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Preference Questionnaire Version 1
Description: Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
Study: NCT05029700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: Control group (CG) performed 30 minutes of aerobic training.CG received treatment 2 times a week for 8 weeks. Aerobic training (AT) was given using a treadmill. A heart rate monitor (Polar V800™, Finland) was used by each patient to follow their heart rates during the AT. During AT, the target heart rate was calculated as 60-80% of maximum heart rates (MHR). Each exercise session consisted of a 5-minutes warm-up, 20 minutes of walking, and 5 minutes cool down on the treadmill.
Study: NCT03992729

Intervention type: DRUG
Intervention: Pregnant women exposed to tildrakizumab
Description: Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy

Intervention type: DRUG
Intervention: Pregnant women not exposed to tildrakizumab
Description: Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
Study: NCT00586131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ammonium chloride or sodium citrate/citric acid
Description: Dose dictated by changes in pH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium citrate/citratic acid
Description: dictated by pH
Study: NCT04208568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Four ports laparoscopic cholecystectomy under general anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Four ports laparoscopic cholecystectomy under general anaesthesia
Study: NCT04012125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible thoracolumbar brace
Description: Subjects would wear the flexible thoracolumbar brace over 18 hours a day
Study: NCT01066000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
Study: NCT02562768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3154207
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT01422252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigi'Fall®
Description: Precocious fall detection device
Study: NCT03260920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Intranasal Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Intranasal Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Intranasal Oxytocin
Study: NCT02755298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04209881

Intervention type: OTHER
Intervention: ovarian reserve for Ankylosing spondylitis and control groups
Description: Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded.

Intervention type: OTHER
Intervention: ovarian reserve for Ankylosing spondylitis and control groups
Description: Additional organ diseases due to the pathophysiology of the disease may be seen in women with ankylosing spondylitis. therefore, we established the first group of women with the diagnosis of ankylosing spondylitis.~Women Who Are Diagnosed With Ankylosing Spondylitis Will Form The Study Group. and health women will be control group.~Clinical And Laboratory Parameters Will Be Evaluated For Ovarian Capacity Of These Women.~Amh Will Be Looked For (Pmol / L). Antral Folukul Census In The Overin Folukular Stage Will Be Valued As Number. Fsh (Iu / L) And Estradiol (Pmol / L) Values Will Also Be Recorded.
Study: NCT04994262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Lozenge
Description: In the study, Oka Menthol, a herbal lozenge produced by Otacı, will be used. Its formula contains: menthol 0.26%, eucalyptol 0.065%, thymol 0.0002%, camphor 0.0002%, anise oil, thyme oil, coltsfoot, marshmallow flower, bovine tail flower extracts, glucose and sucrose.~Medical properties: Otacı Oka Menthol Pastil shows antibacterial and fungicidal properties with eucalyptol in its composition. Menthol is effective against local anesthetic, local antitussive and irritation. It also plays a mild analgesic role with camphor in its content. It has an antibacterial and antifungal effect with thymol, a phenolic antiseptic. Otaco Oka Menthol Pastilles also contain extracts of coltsfoot, cow's tail flower and marshmallow flower which are anti-irritant and expectorant.
Study: NCT03049696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENCOURAGEING START
Description: 16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.